17 hours Ago By ABMN Staff
Disc Medicine, Inc. ( NASDAQ:IRON – Get Free Report ) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,480,000 shares, an increase of 9.
6% from the August 15th total of 1,350,000 shares. Approximately 9.6% of the shares of the company are sold short.
Based on an average trading volume of 297,200 shares, the short-interest ratio is presently 5.0 days. Institutional Trading of Disc Medicine A number of institutional investors have recently bought and sold shares of IRON.
Perceptive Advisors LLC increased its position in Disc Medicine by 14.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company’s stock worth $59,091,000 after purchasing an additional 127,404 shares in the last quarter.
Frazier Life Sciences Management L.P. lifted its stake in shares of Disc Medicine by 19.
8% in the fourth quarter. Frazier Life Sciences Management L.P.
now owns 785,000 shares of the company’s stock valued at $45,342,000 after buying an additional 130,000 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in shares of Disc Medicine in the first quarter valued at $7,429,000.
Jennison Associates LLC raised its holdings in shares of Disc Medicine by 349.1% in the first quarter. Jennison Associates LLC now owns 193,240 shares of the company’s stock valued at $12,031,000 after purchasing an additional 150,209 shares during the last quarter.
Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Disc Medicine by 59.8% in the first quarter.
Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock valued at $58,788,000 after purchasing an additional 353,382 shares during the last quarter. Institutional investors own 83.
70% of the company’s stock. Disc Medicine Trading Up 0.6 % Shares of Disc Medicine stock traded up $0.
30 during midday trading on Wednesday, reaching $47.65. The company had a trading volume of 147,939 shares, compared to its average volume of 356,980.
The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -14.10 and a beta of 0.
59. The stock has a fifty day simple moving average of $46.97 and a 200 day simple moving average of $43.
43. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $77.
60. Wall Street Analysts Forecast Growth Several research analysts have weighed in on the stock. Wedbush restated an “outperform” rating and set a $57.
00 target price on shares of Disc Medicine in a research report on Friday, August 9th. Wells Fargo & Company assumed coverage on Disc Medicine in a report on Thursday, August 22nd. They issued an “overweight” rating and a $75.
00 target price on the stock. BMO Capital Markets restated an “outperform” rating and set a $70.00 price objective (up previously from $50.
00) on shares of Disc Medicine in a research note on Monday, June 17th. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Disc Medicine in a research note on Monday.
Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research note on Tuesday, May 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock.
Based on data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and an average target price of $64.13. Read Our Latest Research Report on IRON Disc Medicine Company Profile ( Get Free Report ) Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Read More Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter .
.
